CytoDel announces successful intra-neuronal antibody delivery without a viral vector
New York City, January 6, 2021 — CytoDel, Inc. («CytoDel» or «the Company»), a privately-held corporation, today announces the publication of preclinical data on the Company’s lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine. The complete text of the article titled, «Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism,»…
Details